Cargando…
PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma
Despite various treatment attempts, the heterogenous group of soft tissue sarcomata (STS) with more than 100 subtypes still shows poor outcomes. Therefore, effective biomarkers for prognosis prediction and personalized treatment are of high importance. The Procollagen-Lysine, 2-Oxoglutarate 5-Dioxyg...
Autores principales: | Gong, Siming, Schopow, Nikolas, Duan, Yingjuan, Wu, Changwu, Kallendrusch, Sonja, Osterhoff, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141206/ https://www.ncbi.nlm.nih.gov/pubmed/35627171 http://dx.doi.org/10.3390/genes13050787 |
Ejemplares similares
-
A Human Pan-Cancer System Analysis of Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3)
por: Gong, Siming, et al.
Publicado: (2021) -
Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma
por: Wu, Changwu, et al.
Publicado: (2022) -
Integrative and Comprehensive Pancancer Analysis of Regulator of Chromatin Condensation 1 (RCC1)
por: Wu, Changwu, et al.
Publicado: (2021) -
A Novel Four-Gene Prognostic Signature for Prediction of Survival in Patients with Soft Tissue Sarcoma
por: Wu, Changwu, et al.
Publicado: (2021) -
A tumor microenvironment-based prognostic index for osteosarcoma
por: Wu, Changwu, et al.
Publicado: (2023)